Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Treatment
  4. /
  5. rimeporide

rimeporide

September 28, 2017
rimeporide
Trade Name
Orphan Indication Duchenne muscular dystrophy
USA Market Approval USA
USA Designation Date 2017-09-19 00:00:00
Sponsor EspeRare Foundation;14, Ch des Aulx;Plan-les-Ouates
Related Access Program
PTC Therapeutics – Duchenne Muscular Dystrophy Marathon Pharmaceuticals, LLC. – Duchenne muscular dystrophy PTC Therapeutics International Limited – Duchenne muscular dystrophy

Related Treatment

  • Edasalonexent
  • Adeno-associated viral vector differentially expressing microdystrophi
  • Partial myostatin antigen displayed on the surface of Lactobacillus ca
  • Non-replicating recombinant adeno-associated virus vector containing 4
  • Cosyntropin
More Treatment
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2024 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo